Detalhe da pesquisa
1.
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Eur J Clin Pharmacol
; 75(11): 1565-1574, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392364
2.
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
Eur J Clin Pharmacol
; 74(12): 1593-1604, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30105453
3.
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group studyâ©.
Int J Clin Pharmacol Ther
; 55(1): 41-53, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27443658
4.
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group studyâ©.
Int J Clin Pharmacol Ther
; 55(1): 54-65, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27841151
5.
Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs.
J Cardiovasc Pharmacol
; 63(2): 120-31, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24126567
6.
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38389387
7.
Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.
Drug Metab Dispos
; 41(5): 1046-59, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23431113
8.
Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals.
Clin Transl Sci
; 16(10): 1758-1767, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688315
9.
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
J Interferon Cytokine Res
; 43(6): 246-256, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454249
10.
Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.
Psychopharmacology (Berl)
; 239(1): 1-13, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34773483
11.
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.
Clin Ther
; 42(1): 175-195, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31926605
12.
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Clin Pharmacokinet
; 58(3): 349-361, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30088221
13.
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
J Clin Pharmacol
; 48(12): 1411-9, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18827075
14.
Impact of siponimod on vaccination response in a randomized, placebo-controlled study.
Neurol Neuroimmunol Neuroinflamm
; 4(6): e398, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28955715
15.
Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects.
Clin Ther
; 38(3): 631-45.e1, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26916566
16.
Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Clin Ther
; 37(11): 2489-2505.e2, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26519230
17.
AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
Br J Pharmacol
; 172(5): 1292-304, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25363835
18.
Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.
Eur J Pharm Sci
; 49(5): 836-44, 2013 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23770377
19.
Drug interactions during therapy with three major groups of antimicrobial agents.
Expert Opin Pharmacother
; 7(6): 639-51, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16556082